Access to the latest research — for scientists and people living with PD alike — in PDF's new scientific journal.
Schwarz Pharma’s NDA for Rotigotine Transdermal System is filed by FDA
- Apr 01 2005
Schwarz Pharma announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for rotigotine transdermal system on March 29, 2005. The European Medical Agency, EMEA, had already accepted the submission in October 2004. Rotigotine has been formulated as a transdermal delivery system, a patch.
Source Date: Apr 01 2005
Source Publication: Schwarz Pharma
View source URL